secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001213900-24-005780
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed forms JV with HTIT for oral insulin; HTIT contributes $70M, Oramed $20M + IP
--------------------------------------------------------------------------------

- Joint venture will develop oral insulin and POD technology; HTIT contributes $70M cash, Oramed $10M cash + $10M in ORMP shares.
- Oramed transfers intellectual property to JV; receives 3% royalty on gross revenues from Oramed-related assets.
- JV intends to initiate a Phase 3 oral insulin trial in the United States.
- Closing contingent on signing ancillary agreements within 3 months and obtaining IIA approval (estimated redemption fee $2M-$6M).
- Initially 50/50 ownership; HTIT has option to invest up to $20M more for increased equity stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024005780/0001213900-24-005780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024005780/ea192032-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-005780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer